Booster take-up disparities widen Striking contrasts in booster coverage are emerging in different local government areas. What can be done to address the inequities?
First safety data on Novavax released Early information on the administration of the Novavax vaccine in Australia is in line with clinical trials data, the TGA has reported.
Booster protection wanes after four months – what does this mean for winter in Australia? The US CDC’s latest report on the durability of booster protection has found a more than 20% decline in effectiveness against emergency department encounters.
TGA approval clarifies AstraZeneca booster use While vaccinators could already use AstraZeneca as a booster in certain circumstances, the TGA decision may make the option clearer to the public.
Fourth dose now recommended for cancer patients over 16 The change in ATAGI advice will affect the COVID vaccine recommendations for cancer patients aged 16 and 17 with immediate effect.
ATAGI releases clinical information for teen boosters Around 65% of teenagers aged 16 and over are now eligible to receive a COVID booster vaccine.
Does mixing COVID boosters provide better immunity? GP Dr Anna Samecki investigates whether it is better to mix or match the third COVID-19 booster dose.
Omicron variant and do we need eternal boosters? Professor Paul Effler, Senior Medical Advisor, Communicable Disease Control Directorate in the Department of Health, joins The Good GP to discuss how Omicron behaves and compares to the other variants.
TGA releases updated COVID booster safety data Swollen lymph nodes have been the most commonly reported adverse effect to emerge from Australia’s booster program.
ATAGI approves fourth dose for severely immunocompromised Described as a booster – rather than part of the primary vaccination course – people are eligible four months after their third dose.